# To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

> **NCT06365879** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 392 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** CMAB007
- **DRUG:** Xolair

## Key facts

- **NCT ID:** NCT06365879
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-18
- **Primary completion:** 2026-01-29
- **Final completion:** 2026-07-01
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365879, "To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06365879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*